Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Welcome to the TNL Beta! We are actively improving this experience.

Share Feedback

Source study found

Story checked

Stronger cholesterol treatment shrinks more plaque in heart arteries, new clinical trial finds (opens in a new tab)

medicalxpress.com · 2026-11-05

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 6 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Notice: Analysis is currently derived from study abstracts. Full-text paper analysis capabilities are currently in development.

Share this check

Help improve NewsLink

Tell us what worked or what needs attention in this check.

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Six of seven claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 6 supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

7 claims in this story

Showing all 7 claimsChoose a verdict to focus the list.

Claim 1 of 7Not coveredThe article says calcified plaque volume increased modestly in both groups, indicating plaque stabilization, and further investigation is needed to know whether the greater reduction translates into fewer cardiovascular events.View evidenceHide evidence

Why this verdict

The abstract profile supports that calcified plaque volume increased similarly in both groups, but it does not verify the story’s interpretation that this indicated plaque stabilization. The profile also does not provide an explicit abstract-level statement about needing further investigation to determine whether plaque regression translates into fewer cardiovascular events, although that caveat is consistent with the fact that the reported endpoints were imaging outcomes rather than clinical events.

1

Study evidence

Total plaque volume (TPV) decreased at 18 months in both arms, with significantly greater regression in the more intensive-therapy group compared with the intensive-therapy group.-30.9 mm3 (95% CI, -57.2 to -4.5 mm3); P = .02

“FLOWPROMOTE was a multicenter randomized clinical trial enrolling statin-naive patients with newly diagnosed stable CAD”
Claim 2 of 7SupportedIn a recent randomized clinical trial called FLOWPROMOTE, researchers present a strategy to reverse atherosclerosis partially.View evidenceHide evidence

Why this verdict

The abstract profile supports that FLOWPROMOTE was a randomized trial in statin-naive stable CAD patients and that more intensive lipid-lowering therapy produced greater regression of total and noncalcified coronary plaque over 18 months. The story’s hedged phrasing of a strategy to partially reverse atherosclerosis is consistent with plaque-volume regression measured by coronary CTA, though it should be understood as an imaging endpoint rather than proven clinical event reduction.

1

Study evidence

Total plaque volume (TPV) decreased at 18 months in both arms, with significantly greater regression in the more intensive-therapy group compared with the intensive-therapy group.-30.9 mm3 (95% CI, -57.2 to -4.5 mm3); P = .02

“FLOWPROMOTE was a multicenter randomized clinical trial enrolling statin-naive patients with newly diagnosed stable CAD”
Claim 3 of 7SupportedThe trial tested whether aggressively lowering LDL cholesterol in newly diagnosed patients using cholesterol-lowering statins can shrink and reverse plaque buildup in heart arteries.View evidenceHide evidence

Why this verdict

The trial did test whether more intensive LDL-lowering therapy could reduce coronary plaque burden, using serial CTA endpoints for total, noncalcified, and calcified plaque volume. The wording is somewhat simplified because one arm used rosuvastatin plus ezetimibe rather than statin alone, but the core claim that the RCT tested plaque shrinkage/regression with aggressive lipid lowering is supported.

1

Study evidence

Total plaque volume (TPV) decreased at 18 months in both arms, with significantly greater regression in the more intensive-therapy group compared with the intensive-therapy group.-30.9 mm3 (95% CI, -57.2 to -4.5 mm3); P = .02

“FLOWPROMOTE was a multicenter randomized clinical trial enrolling statin-naive patients with newly diagnosed stable CAD”
Claim 4 of 7SupportedOver an 18-month treatment period, participants either took atorvastatin 40 mg daily or rosuvastatin 40 mg plus ezetimibe 10 mg daily.View evidenceHide evidence

As stated18 months

Why this verdict

The abstract profile states that patients were randomized for 18 months to atorvastatin 40 mg or rosuvastatin 40 mg plus ezetimibe 10 mg.

1

Study evidence

Total plaque volume (TPV) decreased at 18 months in both arms, with significantly greater regression in the more intensive-therapy group compared with the intensive-therapy group.-30.9 mm3 (95% CI, -57.2 to -4.5 mm3); P = .02

“FLOWPROMOTE was a multicenter randomized clinical trial enrolling statin-naive patients with newly diagnosed stable CAD”
Claim 5 of 7SupportedWith combination therapy, 90% of patients saw their plaque volume decrease, compared with 75% on standard treatment.View evidenceHide evidence

As stated90% vs 75%

Why this verdict

The profile reports total plaque volume regression in 47/52 patients, or 90%, with more intensive therapy versus 38/51, or 75%, with intensive atorvastatin therapy.

1

Study evidence

Total plaque volume (TPV) decreased at 18 months in both arms, with significantly greater regression in the more intensive-therapy group compared with the intensive-therapy group.-30.9 mm3 (95% CI, -57.2 to -4.5 mm3); P = .02

“FLOWPROMOTE was a multicenter randomized clinical trial enrolling statin-naive patients with newly diagnosed stable CAD”
Claim 6 of 7SupportedMore intensive combination therapy lowered LDL cholesterol by 65%, from 127.4 mg/dL to 42.5 mg/dL, compared with a 38% reduction with standard intensive therapy.View evidenceHide evidence

As stated65% vs 38%; 127.4 mg/dL to 42.5 mg/dL

Why this verdict

The profile reports LDL-C decreasing from 127.4 to 42.5 mg/dL, a 65% reduction, with rosuvastatin plus ezetimibe, compared with a 38% reduction in the atorvastatin arm.

1

Study evidence

Total plaque volume (TPV) decreased at 18 months in both arms, with significantly greater regression in the more intensive-therapy group compared with the intensive-therapy group.-30.9 mm3 (95% CI, -57.2 to -4.5 mm3); P = .02

“FLOWPROMOTE was a multicenter randomized clinical trial enrolling statin-naive patients with newly diagnosed stable CAD”
Claim 7 of 7SupportedTotal plaque volume shrank by 21.1% with combination therapy, compared with 13.6% with standard treatment, and noncalcified plaque shrank by 28.2% versus 20%.View evidenceHide evidence

As stated21.1% vs 13.6%; 28.2% vs 20%

Why this verdict

The profile reports total plaque volume decreased by 21.1% with more intensive therapy versus 13.6% with intensive therapy, and noncalcified plaque volume decreased by 28.2% versus 20.0%.

1

Study evidence

Total plaque volume (TPV) decreased at 18 months in both arms, with significantly greater regression in the more intensive-therapy group compared with the intensive-therapy group.-30.9 mm3 (95% CI, -57.2 to -4.5 mm3); P = .02

“FLOWPROMOTE was a multicenter randomized clinical trial enrolling statin-naive patients with newly diagnosed stable CAD”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Lower achieved LDL-C levels were linearly associated with greater regression of total plaque volume and noncalcified plaque volume in a secondary post-randomization association analysis.

    The profile identifies this as a secondary contribution, but the story presentation does not clearly distinguish the achieved-LDL observational association from the randomized treatment comparison.

    From secondary observational analysis within RCT cohort

6 things the story did carry across
  • FLOWPROMOTE was a multicenter randomized clinical trial in statin-naive patients with newly diagnosed stable coronary artery disease, comparing atorvastatin 40 mg with rosuvastatin 40 mg plus ezetimibe 10 mg for 18 months.
  • The reported plaque outcomes were prespecified secondary imaging endpoints measured by serial coronary CTA, not clinical cardiovascular event outcomes.
  • More intensive lipid-lowering therapy produced significantly greater regression of total plaque volume and noncalcified plaque volume than atorvastatin 40 mg at 18 months.
  • More intensive therapy achieved lower LDL-C than intensive atorvastatin therapy, with LDL-C falling from 127.4 to 42.5 mg/dL versus a 38% reduction in the atorvastatin arm.
  • A higher proportion of patients had total plaque volume regression with more intensive therapy: 47/52, or 90%, versus 38/51, or 75%, with intensive therapy.
  • Calcified plaque volume increased similarly in both treatment groups; the abstract profile does not verify a stabilization interpretation.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoCompare intensive vs more intensive lipid-lowering therapy for coronary plaque regression over 18 months in statin-naive patients with stable CAD using serial coronary CTA (prespecified secondary imaging endpoints).Randomized clinical trialExpand

In plain English

Prespecified secondary imaging analysis of the FLOWPROMOTE randomized trial (statin‑naive stable CAD) comparing atorvastatin 40 mg (intensive) vs rosuvastatin 40 mg + ezetimibe 10 mg (more intensive) over 18 months using serial coronary CTA to quantify total plaque volume (TPV), noncalcified plaque volume (NCPV), and calcified plaque volume (CPV). More intensive therapy produced significantly greater regression of TPV and NCPV at 18 months; CPV increased similarly in both groups. Achieved LDL‑C was lower with more intensive therapy and was linearly associated with greater plaque regression.

Key findings

  • Total plaque volume (TPV) decreased at 18 months in both arms, with significantly greater regression in the more intensive-therapy group compared with the intensive-therapy group.-30.9 mm3 (95% CI, -57.2 to -4.5 mm3); P = .02
  • Noncalcified plaque volume (NCPV) decreased at 18 months in both arms, with significantly greater regression in the more intensive-therapy group compared with the intensive-therapy group.-28.9 mm3 (95% CI, -53.2 to -4.6 mm3); P = .02
“FLOWPROMOTE was a multicenter randomized clinical trial enrolling statin-naive patients with newly diagnosed stable CAD”
2human in vivoAssess the association between achieved LDL-C levels and the magnitude of coronary plaque regression (dose-response relationship) across participants.secondary observational analysis within RCT cohortExpand

In plain English

In a prespecified secondary analysis of the FLOWPROMOTE trial (n=104 statin‑naive patients with stable CAD), achieved LDL-C measured during follow-up was analyzed as a continuous exposure and reported to be linearly associated with the magnitude of coronary plaque regression measured by serial coronary CTA (total plaque volume and noncalcified plaque volume). Lower achieved LDL‑C correlated with greater regression of TPV and NCPV.

Key findings

  • Lower achieved LDL‑C levels were linearly associated with greater regression of total plaque volume (TPV) and noncalcified plaque volume (NCPV) measured by serial coronary CTA.
“Lower achieved LDL-C levels were linearly associated with greater regression of TPV and NCPV.”
What this piece can’t prove
  • Abstract does not specify whether or how the association model adjusted for potential confounders (baseline plaque burden, clinical covariates, adherence, etc.).
  • As a postrandomization (secondary) analysis, the association may be subject to bias from factors that influence achieved LDL‑C after randomization.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

P630Comparison of plaque microstructures between two high-intensity statin therapies: rosuvastatin versus atorvastatin

European Heart Journal · 2017 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.